AstraZeneca (AZN,AZN.L,ZEG.DE,AZN.ST) said the FDA's Oncologic Drugs Advisory Committee or ODAC has recognised a favourable benefit risk profile for AstraZeneca's Truqap in combination with abiraterone and androgen deprivation therapy for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 Phase III trial. The Committee voted 7 to 1, with 1 abstaining.
In August 2025, the FDA accepted the sNDA for Truqap in combination with abiraterone and ADT. The ODAC provides the FDA with independent, expert advice on marketed and investigational medicines for use in the treatment of cancer. The FDA will consider the feedback as it reviews the submission.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.